GALAPAGOS EXTENDS AMGEN DEAL, STOCK SURGES

A A

Galapagos (GLPG.BR: Quote, Profile, Research) has extended a deal between recently acquired BioFocus (BIO.L: Quote, Profile, Research) and Amgen (AMGN.O: Quote, Profile, Research) to provide research services to the U.S. biotechnology giant, sending its stock up more than eight percent. Galapagos (GLPG.AS: Quote, Profile, Research) said on Wednesday it would receive an upfront fee of $2.3 million under the terms of the extended deal, which was first signed between BioFocus and Amgen in 2003.

Reuters (http://today.reuters.com/business/newsArticle.aspx?type=health&storyID=nL07406368)